AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** Stabilizing formulation for immunoglobulins G compositions, ~~characterised in that~~ wherein the formulation includes a sugar alcohol, glycine, and a non-ionic detergent, in order to be suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form.

2. **(Original)** Formulation according to claim 1, consisting of the said sugar alcohol, glycine and non-ionic detergent.

3. **(Currently Amended)** Formulation according to any one of claims 1 and 2, ~~characterized in that~~ wherein the sugar alcohol is mannitol.

4. **(Currently Amended)** Formulation according to claim 3, ~~characterized in that~~ wherein the concentration of mannitol is between 30 g/l and 50 g/l.

5. **(Currently Amended)** Formulation according to ~~any one of claims 1 and 4~~ claim 1, characterized in that the concentration of glycine is between 7 g/l and 10 g/l.

6. **(Currently Amended)** Formulation according to ~~any one of claims 1 and 5~~ claim 1, ~~characterized in that~~ wherein the concentration of the non-ionic detergent is between 20 and 50 ppm.

7. **(Currently Amended)** Immunoglobulins G composition in liquid form, comprising the stabilising formulation according to ~~any one of claims 1 to 6~~ claim 1.

8. **(Currently Amended)** Imunnoglobulins G composition in lyophilised form, comprising the stabilising formulation according to ~~any one of claims 1 to 6~~ claim 1.

9. **(Currently Amended)** Immunoglobulins G composition according to claim 7, ~~characterized in that it~~ wherein the composition includes an amount of polymers less than 0.3 % after a 6 months storage period at room temperature.

10. **(Currently Amended)** Immunoglobulins G composition according to claim 8, ~~characterized in that it~~ wherein the composition includes an amount of polymers less than 0.3 % after a 12 months storage period at room temperature or for 6 months at 40°C.

11. **(Currently Amended)** Immunoglobulins G composition according to ~~any one of claims 7 to 10, characterized in that it~~ claim 1, wherein the composition includes an amount of dimers less than 7 % after a 24 months storage period at 4°C.

12. **(Currently Amended)** ~~Use of a~~ A method of stabilising ~~formulation according to any one of claims 1 to 6, for stabilisation of~~ an immunoglobulin~~s~~ G composition~~s~~ in liquid form obtained directly by fractioning of human plasma, said method comprising combining said polyclonal immunoglobulin G composition with a stabilising formulation according to claim 1.

13. **(Currently Amended)** ~~Use of a~~ A method of stabilising ~~formulation according to any one of claims 1 to 6, for stabilisation of~~ an immunoglobulins G compositions in lyophilised form, said method comprising combining said polyclonal immunoglobulin G composition with a stabilising formulation according to claim 1.

14. **(Currently Amended)** ~~Use of a~~ A method of stabilising ~~formulation according to any one of claims 1 to 6, for stabilisation of~~ an immunoglobulin~~s~~ G composition~~s~~ in liquid form obtained after reconstitution in a suitable aqueous medium of an immunoglobulin~~s~~ G composition~~s~~ in lyophilised form, said method comprising combining said polyclonal immunoglobulin G composition with a stabilising formulation according to claim 1.